Moving targets: COVID-19 vaccine efficacy against Omicron subvariants.
作者信息
da Silva Maria Karolaynne, Fulco Umberto Laino, Júnior Edilson Dantas da Silva, Oliveira Jonas Ivan Nobre
机构信息
Department of Biophysics and Pharmacology, Bioscience Center, Federal University of Rio Grande do Norte, 59078-900, Natal/RN, Brazil.
Department of Biophysics and Pharmacology, Bioscience Center, Federal University of Rio Grande do Norte, 59078-900, Natal/RN, Brazil.
出版信息
Mol Ther. 2022 Aug 3;30(8):2644-2645. doi: 10.1016/j.ymthe.2022.07.004. Epub 2022 Jul 31.
Abstract
摘要
相似文献
1
Moving targets: COVID-19 vaccine efficacy against Omicron subvariants.
Mol Ther. 2022 Aug 3;30(8):2644-2645. doi: 10.1016/j.ymthe.2022.07.004. Epub 2022 Jul 31.
2
Assessing COVID-19 vaccine effectiveness against Omicron subvariants: Report from a meeting of the World Health Organization.
Vaccine. 2023 Mar 31;41(14):2329-2338. doi: 10.1016/j.vaccine.2023.02.020. Epub 2023 Feb 9.
3
Immunogenicity, clinical efficacy and safety of additional second COVID-19 booster vaccines against Omicron and its subvariants: A systematic review.
Rev Med Virol. 2024 Jan;34(1):e2515. doi: 10.1002/rmv.2515.
4
Durability of XBB.1.5 Vaccines against Omicron Subvariants.
N Engl J Med. 2024 Jun 13;390(22):2124-2127. doi: 10.1056/NEJMc2402779. Epub 2024 May 29.
5
COVID-19 vaccine effectiveness against severe disease from SARS-CoV-2 Omicron BA.1 and BA.2 subvariants - surveillance results from southern Sweden, December 2021 to March 2022.
Euro Surveill. 2022 May;27(18). doi: 10.2807/1560-7917.ES.2022.27.18.2200322.
6
Comparative immunogenicity of monovalent and bivalent adenovirus vaccines carrying spikes of early and late SARS-CoV-2 variants.
Emerg Microbes Infect. 2024 Dec;13(1):2387447. doi: 10.1080/22221751.2024.2387447. Epub 2024 Aug 19.
7
A spike-trimer protein-based tetravalent COVID-19 vaccine elicits enhanced breadth of neutralization against SARS-CoV-2 Omicron subvariants and other variants.
Sci China Life Sci. 2023 Aug;66(8):1818-1830. doi: 10.1007/s11427-022-2207-7. Epub 2022 Dec 30.
8
Neutralization of Omicron subvariants BA.1 and BA.5 by a booster dose of COVID-19 mRNA vaccine in a Japanese nursing home cohort.
Vaccine. 2023 Mar 24;41(13):2234-2242. doi: 10.1016/j.vaccine.2023.02.068. Epub 2023 Feb 27.
9
SARS-CoV-2 Omicron subvariants exhibit distinct fusogenicity, but similar sensitivity, to pan-CoV fusion inhibitors.
Emerg Microbes Infect. 2023 Dec;12(1):2178241. doi: 10.1080/22221751.2023.2178241.
10
Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.
MMWR Morb Mortal Wkly Rep. 2022 Jan 21;71(4):139-145. doi: 10.15585/mmwr.mm7104e3.
引用本文的文献
1
Therapeutic Potential of Neutralizing Monoclonal Antibodies (nMAbs) against SARS-CoV-2 Omicron Variant.
Curr Pharm Des. 2025;31(10):753-773. doi: 10.2174/0113816128334441241108050528.
2
Insights into structural vaccinology harnessed for universal coronavirus vaccine development.
Clin Exp Vaccine Res. 2024 Jul;13(3):202-217. doi: 10.7774/cevr.2024.13.3.202. Epub 2024 Jul 31.
3
Timing of maternal vaccination against COVID-19 for effective protection of neonates: cohort study.
Front Immunol. 2024 Jul 8;15:1359209. doi: 10.3389/fimmu.2024.1359209. eCollection 2024.
4
A newly discovered circovirus and its potential impact on human health and disease.
Int J Surg. 2024 May 1;110(5):2523-2525. doi: 10.1097/JS9.0000000000001198.
5
Multicomponent intranasal adjuvant for mucosal and durable systemic SARS-CoV-2 immunity in young and aged mice.
NPJ Vaccines. 2023 Jun 29;8(1):96. doi: 10.1038/s41541-023-00691-1.
6
A multicomponent intranasal adjuvant drives durable humoral, cellular, and mucosal immune responses to SARS-CoV-2 in young and aged mice.
Res Sq. 2023 Jan 20:rs.3.rs-2457013. doi: 10.21203/rs.3.rs-2457013/v1.
本文引用的文献
1
Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5.
Nature. 2022 Aug;608(7923):603-608. doi: 10.1038/s41586-022-05053-w. Epub 2022 Jul 5.
2
Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum.
Cell. 2022 Jul 7;185(14):2422-2433.e13. doi: 10.1016/j.cell.2022.06.005. Epub 2022 Jun 9.
3
Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5.
N Engl J Med. 2022 Jul 7;387(1):86-88. doi: 10.1056/NEJMc2206576. Epub 2022 Jun 22.
4
BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection.
Nature. 2022 Aug;608(7923):593-602. doi: 10.1038/s41586-022-04980-y. Epub 2022 Jun 17.
5
Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies.
Lancet Infect Dis. 2022 Jul;22(7):942-943. doi: 10.1016/S1473-3099(22)00365-6. Epub 2022 Jun 9.
6
Are COVID surges becoming more predictable? New Omicron variants offer a hint.
Nature. 2022 May;605(7909):204-206. doi: 10.1038/d41586-022-01240-x.
7
mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant.
Cell Rep Med. 2022 Jan 24;3(2):100529. doi: 10.1016/j.xcrm.2022.100529. eCollection 2022 Feb 15.
8
Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera.
Science. 2022 Feb 11;375(6581):678-680. doi: 10.1126/science.abn7591. Epub 2022 Jan 18.
9
Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies.
Nature. 2022 Feb;602(7898):657-663. doi: 10.1038/s41586-021-04385-3. Epub 2021 Dec 23.
10
SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies.
Nature. 2020 Dec;588(7839):682-687. doi: 10.1038/s41586-020-2852-1. Epub 2020 Oct 12.
Zotero 插件